Aptose Biosciences (NASDAQ:APTO) Upgraded by Alliance Global Partners to Strong-Buy Rating

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by investment analysts at Alliance Global Partners to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

A number of other research firms have also commented on APTO. StockNews.com started coverage on Aptose Biosciences in a research note on Tuesday. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, February 12th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Aptose Biosciences has an average rating of “Buy” and a consensus target price of $130.00.

Aptose Biosciences Stock Down 1.8 %

APTO opened at $3.19 on Thursday. The firm has a market cap of $6.83 million, a P/E ratio of -1.07 and a beta of 0.88. Aptose Biosciences has a 52 week low of $3.05 and a 52 week high of $57.00. The business’s fifty day simple moving average is $5.92 and its 200 day simple moving average is $8.83.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP bought a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned 4.15% of Aptose Biosciences as of its most recent filing with the SEC. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.